>>PfDHODH-IN-2

PfDHODH-IN-2

Catalog No.GC61177

디히드로티오페논 유도체(화합물 11)인 PfDHODH-IN-2는 IC50이 1.11μM인 강력한 열대열원충돌원충 디히드로오로테이트 탈수소효소(PfDHODH) 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

PfDHODH-IN-2 Chemical Structure

Cas No.: 425629-94-3

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$168.00
재고 있음
5mg
US$153.00
재고 있음
10mg
US$234.00
재고 있음
25mg
US$441.00
재고 있음
50mg
US$684.00
재고 있음
100mg
US$945.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria[1].

Malaria is a global parasitic infectious disease caused by Plasmodium parasites, among which Plasmodium falciparum is the most dangerous one with the highest rates of complications and mortality[1].PfDHODH-IN-2 shows an overall selectivity for PfDHODH (IC50=1.113 µM) over hDHODH (IC50>50 µM). PfDHODH-IN-2 demonstrats in vitro potency against the 3D7 and Dd2 strains of P. falciparum with IC50 values of both >20 µM, respectively in whole cell assays[1].

[1]. Minghao Xu, et al. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives. J Med Chem. 2013 Oct 24;56(20):7911-24.

리뷰

Review for PfDHODH-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PfDHODH-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.